Hip surgery is one of the most common and consequential operations performed in older adults, offering mobility and independence to patients with fractures, arthritis, and other disabling conditions. Yet the procedure also exposes patients to a dangerous postoperative complication: venous thromboembolism, or VTE. This term includes deep-vein thrombosis, in which a clot develops most often in the leg, and pulmonary embolism, in which a clot travels to the lungs. New research is examining whether an event that occurs during the operation itself—intraoperative hypotension—could help identify elderly patients at heightened risk of developing VTE after surgery.

Intraoperative hypotension refers to an abnormal fall in blood pressure while a patient is under anesthesia. It may be defined using an absolute threshold, such as a mean arterial pressure below a specific value, or by considering how far blood pressure drops from the patient’s normal baseline. Mean arterial pressure is particularly important because it reflects the pressure driving blood through vital organs. During hip surgery, blood pressure can fall because of anesthesia-induced widening of blood vessels, blood loss, reduced cardiac output, dehydration, or the physiological stress associated with trauma and inflammation.

The possible connection between low blood pressure during surgery and postoperative thrombosis is biologically complex. At first glance, hypotension and clotting appear to represent opposite problems: one involves insufficient circulation, while the other involves excessive coagulation. In reality, both may arise from a shared physiological disturbance. Reduced blood flow can promote venous stasis, one of the three major elements of Virchow’s triad, which also includes damage to the vessel wall and increased blood coagulability. Prolonged immobility before and after surgery, tissue injury, inflammatory signaling, and activation of platelets and clotting proteins can further intensify this risk.

Hip surgery is an especially important setting in which to study this relationship. Older patients often arrive at the hospital after a fall or fracture, having already experienced reduced mobility, dehydration, pain, and systemic stress. The operation itself can injure tissue and release inflammatory mediators, while postoperative recovery may require several days of limited movement. Age-related changes in the vascular system, a higher prevalence of cancer, heart disease, obesity, and previous thrombosis may add further layers of vulnerability. Together, these factors create a clinical environment in which even modest differences in perioperative circulation could become meaningful.

The research focuses on whether intraoperative blood-pressure patterns can improve the prediction of postoperative VTE beyond conventional risk factors. Rather than treating hypotension as a simple yes-or-no event, investigators may analyze its duration, depth, cumulative exposure, and timing. A brief decline in mean arterial pressure may carry a different implication from a prolonged or repeated episode. The relationship may also depend on whether hypotension occurs during anesthesia induction, the surgical procedure, or the early recovery period, when patients may still be hemodynamically unstable.

To translate these observations into clinical practice, the investigators are constructing a risk prediction model for elderly patients undergoing hip surgery. Such a model could combine intraoperative blood-pressure measurements with demographic, clinical, laboratory, and surgical information. Potential predictors include age, sex, fracture type, preoperative mobility, previous VTE, cancer, cardiovascular disease, renal function, hemoglobin concentration, operative duration, estimated blood loss, transfusion, type of anesthesia, and the timing of postoperative mobilization. The model may also incorporate the use and timing of pharmacological thromboprophylaxis, which commonly includes anticoagulant medications administered after surgery.

A useful prediction model must do more than identify statistical associations. It must be calibrated, meaning that its estimated probabilities should correspond reasonably well with the actual frequency of VTE. It must also discriminate between patients at higher and lower risk, often assessed through measures such as the area under the receiver operating characteristic curve. Internal validation can test whether the model performs consistently within the original dataset, while external validation in a separate hospital or patient population is necessary to determine whether it can generalize beyond the conditions in which it was developed. Without such validation, a model may simply memorize patterns specific to one group of patients.

If the association between intraoperative hypotension and postoperative VTE is confirmed, the findings could influence perioperative monitoring and prevention strategies. Blood pressure management is already central to protecting the brain, heart, and kidneys, but a thrombosis-related signal could broaden the clinical importance of avoiding prolonged hypotension. Patients identified as high risk might receive more intensive surveillance for leg swelling, unexplained tachycardia, chest pain, or oxygen decline. Clinicians could also consider earlier mobilization, closer review of anticoagulant timing, and individualized decisions about the balance between preventing clots and avoiding bleeding.

The study does not necessarily mean that intraoperative hypotension directly causes VTE, and this distinction is critical. Low blood pressure may instead act as a marker of more severe illness, greater blood loss, longer surgery, or a stronger inflammatory response. Older patients with complicated operations may be more likely to experience both hypotension and thrombosis for related but separate reasons. The model’s value will therefore depend on careful adjustment for confounding factors, transparent reporting of missing data, and evaluation across different surgical techniques, anesthesia practices, and thromboprophylaxis protocols. Even with those safeguards, prediction is not the same as prevention. The significance of the work lies in bringing an overlooked intraoperative signal into a broader effort to recognize, stratify, and reduce one of the most serious complications facing older adults after hip surgery.

Subject of Research: The relationship between intraoperative hypotension and postoperative venous thromboembolism in elderly patients undergoing hip surgery, including the development of a risk prediction model.

Article Title: Relationship between intraoperative hypotension and postoperative venous thromboembolism in elderly patients undergoing hip surgery and construction of a risk prediction model

Image Credits: AI Generated

Keywords: Intraoperative hypotension, venous thromboembolism, deep-vein thrombosis, pulmonary embolism, hip surgery, elderly patients, perioperative medicine, risk prediction model, thromboprophylaxis, anesthesia, postoperative complications

Deep venous thrombosis, a condition characterized by the formation of blood clots in deep veins, can lead to serious health risks, including pulmonary embolism. Despite its severity, the underlying mechanisms linking multiple myeloma and DVT remain inadequately understood. This research fills a significant gap by exploring the molecular levels at which these two conditions intersect, illuminating the pathways that could lead to better diagnostic and therapeutic strategies.

The study provides a detailed analysis of the role of miR-503-5p, examining its expression levels and influence within the context of multiple myeloma. The researchers posited that understanding the expression of this microRNA could not only improve the diagnosis of associated venous thromboembolism but also potentially guide treatment strategies tailored to individual patients. Their findings indicate that patients with higher levels of miR-503-5p might experience different disease outcomes, emphasizing the potential of this biomarker in clinical settings.

This discovery has profound implications for improving patient care. Traditionally, diagnosing DVT relies on a combination of clinical assessment, imaging studies, and laboratory tests, which can prove inadequate, especially in late-stage multiple myeloma cases. miR-503-5p as a biomarker offers an innovative approach, potentially streamlining the diagnostic process, thus reducing the risk of misdiagnosis or delay in treatment.

The researchers utilized advanced methodologies to assess the presence and function of miR-503-5p in a series of controlled experiments. Using blood samples from multiple myeloma patients, they employed quantitative real-time polymerase chain reaction technology to measure expression levels of the microRNA, comparing them to control groups. Their meticulous approach ensured a reliable data set, establishing a substantial foundation for the conclusions drawn in the study.

Beyond just diagnosing DVT, miR-503-5p may also unlock new avenues for understanding how multiple myeloma progresses, offering insights into therapeutic targets. The interplay between this microRNA and the coagulation cascade could reveal novel mechanisms of thrombosis in cancer, elucidating why patients with such diseases are more susceptible to clotting disorders. By deepening our understanding of these interactions, clinicians and researchers can develop more effective interventions.

Furthermore, this study does not operate in isolation. The findings contribute to a growing body of literature centered around microRNAs as essential regulators in cancer biology. These small but powerful molecules are increasingly recognized for their role in various biological processes, including cell proliferation, apoptosis, and angiogenesis. Understanding their function provides not just academic value but also practical applications in devising treatment protocols that are more targeted and personalized.

The significance of miR-503-5p and its implications for deep venous thrombosis in multiple myeloma suggests that it warrants further exploration. Subsequent studies may focus on larger patient cohorts, enabling researchers to validate these findings and their clinical utility. In addition, a deeper dive into the regulatory networks involving this microRNA may yield further insights into its role in both cancer progression and thrombotic complications associated with it.

In conclusion, the research conducted by Guo et al. underscores a critical advancement in the field of hematology and oncology, revealing miR-503-5p as a potential dual-purpose biomarker. By linking deep venous thrombosis and multiple myeloma through molecular pathways, this study lays the groundwork for innovative diagnostic and therapeutic strategies. The ongoing exploration of microRNAs in clinical applications highlights an exciting frontier in medicine, suggesting that such molecules may be key players in unraveling the complexities of cancer and its associated complications.

As this research garners attention, it is poised to influence future studies and clinical practices. The integration of such biomarkers into routine evaluations could radically transform the landscape of patient management in multiple myeloma, offering hope for better outcomes among affected individuals. Coupled with continued advancements in molecular research, findings like those reported in this study pave the way for a new era of precision medicine in oncology.

The potential impact of miR-503-5p extends beyond multiple myeloma, offering tantalizing possibilities for understanding thrombosis across various malignancies. As we look to the future, the insights gained from this research will hopefully lead to enhanced preventive measures and treatments, ultimately improving quality of life and survival for patients facing similar challenges.

In summary, the study led by Guo and colleagues stands as a potent reminder of the intricate connections within human biology, illustrating how a seemingly simple molecule can hold the key to understanding complex diseases. As the scientific community delves deeper into the role of microRNAs, the potential for breakthroughs in patient care and treatment personalization remains vast and exciting, reaffirming the importance of continued research in this dynamic field.

Subject of Research: Investigation of miR-503-5p as a biomarker for deep venous thrombosis in multiple myeloma.

Article Title: MiR-503-5p as a potential biomarker for deep venous thrombosis (DVT) in multiple myeloma (MM) and its role in disease development.

Article References:

Guo, Y., Yan, L., Yang, X. et al. MiR-503-5p as a potential biomarker for deep venous thrombosis (DVT) in multiple myeloma (MM) and its role in disease development.
Ann Hematol 104, 6205–6214 (2025). https://doi.org/10.1007/s00277-025-06720-4

Image Credits: AI Generated

DOI: December 2025

Keywords: microRNA, biomarker, deep venous thrombosis, multiple myeloma, cancer research, thrombosis, precision medicine.